Tuesday 29th November
Hear from the CEOs of two local Biotechnology companies focused on novel vaccines against globally significant disease. GPN Vaccines is developing a whole cell vaccine for Streptococcus pneumoniae, the biggest bacterial killer on the planet, which is set to enter clinical trials early in 2023. Sementis is building Australia’s most technologically advanced viral vector vaccine platform focused on applications in infectious disease, pandemic preparedness and allergies.
Prof Tim Hirst, Chairman & CEO of GPN Vaccines
“The need for a pneumococcal vaccine effective against all serotypes”
Tim has extensive expertise in the life sciences, executive management and venture capital investment. Tim was previously CEO of ANU Connect Ventures, a $30M pre-seed VC fund, the Deputy Vice Chancellor for Research & Innovation at The University of Sydney and Professor & Head of Microbiology at the University of Bristol, UK. He is an active angel investor working with investment groups throughout Australia and US to assist early stage companies to raise capital and develop their innovative technologies.
Leanne Hobbs, CEO Sementis
“Unlocking the potential of vaccinia with SCV – Australia’s most advanced viral vector vaccine platform”
Leanne is a global business leader in health care with over 25 years’ experience in the pharmaceutical and vaccine industry both locally and internationally. She is a scientist by training and an international business leader through experience. Inspired by scientists and entrepreneurs, Leanne has taken products from development through to commercialization within the vaccines, pharmaceuticals and consumer healthcare sectors.
Yvette van Eenennaam